Skip Navigation

Annals of Oncology 2008 19(5):827; doi:10.1093/annonc/mdn184
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

in this issue

In this issue

The first 10% of the full text of this article appears below.


   Pemetrexed as second-line treatment for locally advanced or metastatic NSCLC
 
Thirty to forty percent of patients with advanced non-small cell lung cancer (NSCLC) receive second-line treatment after standard first-line platinum-based chemotherapy. Consequently, optimizing second-line treatment has become a major research focus. A randomized phase III trial comparing docetaxel with pemetrexed as second-line therapy for advanced NSCLC has shown that pemetrexed (500 mg/m2, i.v., day 1, q3week) has comparable efficacy to docetaxel, but less toxicity. In this issue, Cullen et al. [pp. 939–945] report the . . . [Full Text of this Article]


   BMI and survival in patients with ovarian cancer
 

   Determinations of LDH in the follow up of myelodysplastic syndromes
 

   Cigarette smoking and site-specific cancer mortality
 

   Quote
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer
M. H. Cullen, P. Zatloukal, S. Sörenson, S. Novello, J. R. Fischer, A. A. Joy, M. Zereu, P. Peterson, C. M. Visseren-Grul, and N. Iscoe
Ann Oncol 2008 19: 939-945. [Abstract] [FREE Full Text]  

Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial
S. V. Barrett, J. Paul, A. Hay, P. A. Vasey, S. B. Kaye, R. M. Glasspool, and On behalf of the Scottish Gynaecological Cancer Trials Group
Ann Oncol 2008 19: 898-902. [Abstract] [FREE Full Text]  

Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes
F. Wimazal, W. R. Sperr, M. Kundi, A. Vales, C. Fonatsch, R. Thalhammer-Scherrer, I. Schwarzinger, and P. Valent
Ann Oncol 2008 19: 970-976. [Abstract] [FREE Full Text]  

Cigarette smoking and site-specific cancer mortality: testing uncertain associations using extended follow-up of the original Whitehall study
G. D. Batty, M. Kivimaki, L. Gray, G. Davey Smith, M. G. Marmot, and M. J. Shipley
Ann Oncol 2008 19: 996-1002. [Abstract] [FREE Full Text]